[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Alice Chung\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":49},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":32,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100523228","phase-2-iit2023-09-chung-upfronttad-upfront-tadsnb-in-patients-with-breast-cancer-with-nodal-metastases-100523228",false,"NCT06092892","IIT2023-09-Chung-UpfrontTAD: Upfront TAD\u002FSNB in Patients With Breast Cancer With Nodal Metastases","IIT2023-09-Chung-UpfrontTAD: Upfront TAD\u002FSNB in Patients With Clinical T1-2N0 ER+ Her2- Breast Cancer With Ultrasound Detected Nodal Metastases","Inclusion Criteria:\n\n* Women age ≥ 45\n* Clinical T1-2N0 ER+ invasive breast cancer\n* US detected biopsy proven axillary nodal disease\n* Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.\n\nExclusion Criteria:\n\n* Palpable nodes on physical exam\n* Her2+ or ER- invasive breast cancer\n* Extranodal extension \\> 3 mm on nodal biopsy\n* More than 2 suspicious nodes on preoperative imaging","FEMALE","45 Years",{"count":19,"type":20},45,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The purpose of the study is to determine the recurrence rates and survival of patients with clinical T1-2N0 ER+\u002FHer2- invasive breast cancer who have biopsy proven image detected nodal disease treated with upfront lumpectomy or mastectomy with TAD followed by adjuvant therapy. This is a prospective, single arm phase II clinical trial. Patients will be screened and enrolled per eligibility criteria. Patient, tumor, and treatment data will be documented.",[26,27,28,29,30,31],"Breast Cancer","Axillary Nodal Disease","Female Breast Cancer","Axilla; Breast","Mastectomy; Lymphedema","Tumor, Breast",[33,34,35],"T1-2N0 ER+ invasive","biopsy","upfront lumpectomy","RECRUITING","2026-05-06",{"date":39,"type":40},"2026-05-11","ACTUAL",{"date":42,"type":40},"2024-04-07",{"date":44,"type":20},"2031-04",{"name":46,"class":47},"Alice Chung","OTHER",3,""]